Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 25,000 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Suma Krishnan also recently made the following trade(s):

• On Friday, December 13th, Suma Krishnan sold 25,000 shares of Krystal Biotech stock. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS traded down $1.02 during trading on Thursday, reaching $177.37. The company had a trading volume of 262,590 shares, compared to its average volume of 289,967. The firm has a market capitalization of $5.11 billion, a price-to-earnings ratio of 59.32 and a beta of 0.87. The stock’s fifty day moving average price is $162.66 and its 200 day moving average price is $174.19. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 earnings per share. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB acquired a new position in shares of Krystal Biotech in the third quarter valued at approximately $40,000. Huntington National Bank grew its holdings in Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after acquiring an additional 283 shares during the period. GF Fund Management CO. LTD. acquired a new position in Krystal Biotech during the fourth quarter worth $95,000. KBC Group NV grew its holdings in Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after acquiring an additional 132 shares during the period. Finally, Covestor Ltd grew its holdings in Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after acquiring an additional 642 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on KRYS shares. Citigroup boosted their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Jefferies Financial Group began coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target on the stock. Chardan Capital lifted their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $220.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).